Clinical Trials with Daunorubicin-DNA and Adriamycin-DNA in Acute Lymphoblastic Leukemia of Childhood, Acute Nonlymphoblastic Leukemia, and Bronchogenic Carcinoma

Overview

Journal Cancer Chemother Pharmacol

Specialty Oncology

Date 1979 Jan 1

PMID 387279

Citations 8

Authors

A Ferrant

R Hulhoven

A Bosly

G Cornu

J L Michaux

G SOKAL

Affiliations

Soon will be listed here.

Abstract

Treatment with daunorubicin-DNA (DNR-DNA) or adriamycin-DNA (ADM-DNA) has been evaluated in acute lymphoblastic leukemia of childhood (ALL), acute nonlymphoblastic leukemia (ANLL) and bronchogenic carcinoma (BC). The Five-year survival rate in 69 children with ALL was 73.7% when ADM-DNA was introduced in the treatment and 38% with DNR-DNA (P = 0.03). A randomization between free DNR and DNR-DNA for remission induction in 26 patients with ANLL has shown that the drugs were of equivalent effectiveness. The one-year survival rate was 66% for the DNR group and 64% for the DNR-DNA group. In 59 patients with BC, a randomized trial between ADM-DNA and cyclophosphamide-vinblastine (CTX-VLB) did not show an advantage in favor of one of these treatments. In anaplastic BC (51 patients), there was no difference in survival rate or remission rate between patients treated with ADM or ADM-DNA. No cardiotoxicity was noted among the patients treated with the complexed drugs. ADM-DNA and DNR-DNA are as effective as the free drugs. Cardiotoxicity appears to be reduced.

Citing Articles

Cryo-shocked cancer cells for targeted drug delivery and vaccination.

Ci T, Li H, Chen G, Wang Z, Wang J, Abdou P Sci Adv. 2020; 6(50).

PMID: 33298439 PMC: 7725453. DOI: 10.1126/sciadv.abc3013.

Comparison of daunorubicin and daunorubicin-DNA complex in the treatment of acute nonlymphoblastic leukemia.

Paul C, Bjorkholm M, Christenson I, ENGSTEDT L, Gahrton G, Hast R Cancer Chemother Pharmacol. 1981; 6(1):65-73.

PMID: 7023715 DOI: 10.1007/BF00253012.

Serum and tissue concentrations of doxorubicin after IV administration of doxorubicin or doxorubicin-DNA complex to patients with gastrointestinal cancer.

Gunven P, Theve N, Peterson C Cancer Chemother Pharmacol. 1986; 17(2):153-6.

PMID: 3719895 DOI: 10.1007/BF00306745.

Human pharmacokinetics of the daunorubicin-DNA complex. An alternative view of the lysosomotropic theory.

Hulhoven R, SOKAL G, Harvengt C Cancer Chemother Pharmacol. 1979; 3(4):243-7.

PMID: 535134 DOI: 10.1007/BF00254739.

Daunorubicin-DNA and doxorubicin-DNA. A review of experimental and clinical data.

Trouet A Cancer Chemother Pharmacol. 1979; 2(1):77-9.

PMID: 498424 DOI: 10.1007/BF00253110.

References

Cornu G, Michaux J, SOKAL G, Trouet A . Daunorubicin-DNA: further clinical trials in acute non-lymphoblastic leukemia. Eur J Cancer (1965). 1974; 10(11):695-700. DOI: 10.1016/0014-2964(74)90106-6. View

Langslet A, Oye I, Lie S . Decreased cardiac toxicity of adriamycin and daunorubicin when bound to DNA. Acta Pharmacol Toxicol (Copenh). 1974; 35(5):379-85. DOI: 10.1111/j.1600-0773.1974.tb00758.x. View

Kummen M, Lie K, Lie S . A pharmacokinetic evaluation of free and DNA-complexed adriamycin: a preliminary study in children with malignant disease. Acta Pharmacol Toxicol (Copenh). 1978; 42(3):212-8. DOI: 10.1111/j.1600-0773.1978.tb02192.x. View

Hulhoven R, Desager J, SOKAL G, Harvengt C . Daunomycin and daunomycinol plasma levels measured by HPLC after perfusions of daunomycin and daunomycin-DNA complex in rabbits: a preliminary report. Arch Int Pharmacodyn Ther. 1977; 226(2):344-5. View

STAQUET M, Rozencweig M, Kenis Y . Pharmacokinetics of adriamycin and adriamycin--DNA complex in L1210 mice and men. Eur J Cancer (1965). 1977; 13(4-5):433-5. DOI: 10.1016/0014-2964(77)90098-6. View

SOKAL G, Trouet A, Michaux J, Cornu G . Letter: DNA-daunorubicin complex: preliminary trials in human leukaemia. Eur J Cancer (1965). 1973; 9(5):391-2. DOI: 10.1016/0014-2964(73)90058-3. View

Trouet A, DE DUVE C . Chemotherapy through lysosomes with a DNA-daunorubicin complex. Nat New Biol. 1972; 239(91):110-2. DOI: 10.1038/newbio239110a0. View

Trouet A, Atassi G . Experimental leukemia chemotherapy with a "lysosomotropic" adriamycin-DNA complex. Eur J Cancer (1965). 1974; 10(7):405-11. DOI: 10.1016/0014-2964(74)90022-x. View

Bosly A, Prignot J, Ledent C, SOKAL G, Trouet A . Adriamycin and adriamycin--DNA in inoperable bronchogenic carcinoma. A randomized study with cyclophosphamide vinblastine. Eur J Cancer (1965). 1978; 14(6):639-44. DOI: 10.1016/0014-2964(78)90297-9. View

10.

Hulhoven R, Desager J . HPLC determination of daunorubicin and daunorubicinol in human plasma. Biomedicine. 1977; 27(3):102-4. View

11.

Cutler S, Ederer F . Maximum utilization of the life table method in analyzing survival. J Chronic Dis. 1958; 8(6):699-712. DOI: 10.1016/0021-9681(58)90126-7. View

12.

Hulhoven R, Desager J . Quantitative determination of low levels of daunomycin and daunomycinol in plasma by high-performance liquid chromatography. J Chromatogr. 1976; 125(1):369-74. DOI: 10.1016/s0021-9673(00)93832-9. View

13.

Hulhoven R, Desager J, Sokai G, Harvengt C . Plasma levels and biotransformation of infused daunorubicin and daunorubicin-DNA complex in rabbits: a preliminary report. Eur J Cancer (1965). 1977; 13(10):1065-9. DOI: 10.1016/0014-2964(77)90002-0. View

14.

Hulhoven R . Daunorubicin, daunorubicinol and DNA plasma kinetics after I.V. administration of daunorubican-DNA complex in the rabbit. Biomedicine. 1978; 29(5):164-7. View